Company profile
Cingulate Inc.
NASDAQ:CINGBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DEXMETHYLPHENIDATE | phase1_2 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04138498 | phase1_2 | completed | 2019-12-06 | 2020-03-06 | Cingulate Therapeutics | CTx-1301 Comparative Bioavailability Study |
| NCT04449250 | phase1 | completed | 2022-09-14 | 2022-10-14 | Cingulate Therapeutics | Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects |
| NCT07119073 | phase1 | completed | 2024-10-31 | 2024-12-21 | Cingulate Therapeutics | In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted) |
| NCT05286762 | phase3 | completed | 2023-08-01 | 2024-02-29 | Cingulate Therapeutics | Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 |
| NCT05924594 | phase3 | suspended | 2023-07-31 | 2027-02-01 | Cingulate Therapeutics | Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 |
FDA applications (0)
No records yet.